Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A simulation-based sample size calculation method for pre-clinical tumor xenograft experiments.

Jianrong Wu1, Shengping Yang2

  • 1a Department of Biostatistics , St. Jude Children's Research Hospital , Memphis , Tennessee , USA.

Journal of Biopharmaceutical Statistics
|April 8, 2017
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reference method matters: DXA system differences influence agreement with 3D optical imaging body composition estimates.

International journal of obesity (2005)·2026
Same author

Correction: Platelet-membrane-biomimetic nanoparticles for targeted antitumor drug delivery.

Journal of nanobiotechnology·2026
Same author

Linking GWAS risk genes to transcriptional features of major depressive disorder via in vivo Perturb-seq.

Nature genetics·2026
Same author

Copper nanoregulator with organelle-level precision reprograms COMMD1-Mediated copper homeostasis for myocardial infarction repair.

Biomaterials·2026
Same author

Childhood violence exposure and the risk of multimorbidity in middle-aged and older adults: A multi-cohort study.

Journal of affective disorders·2026
Same author

From radical/electron competition to interfacial shielding: How PFOA and its derivatives obstruct electrochemical degradation of microplastics.

Journal of hazardous materials·2026

Statistical tests for small pre-clinical tumor xenograft studies often fail, leading to inaccurate sample sizes. A new modified signed log-likelihood ratio test (MSLRT) provides reliable type-I error rates for these experiments.

Area of Science:

  • Pre-clinical research
  • Biostatistics
  • Oncology

Background:

  • Pre-clinical tumor xenograft experiments typically involve small sample sizes (<20) without censored data.
  • Existing statistical tests, often based on large sample approximations, may exhibit inaccurate type-I error rates with skewed data.
  • This can lead to erroneous sample size calculations, impacting experimental reliability.

Purpose of the Study:

  • To address the limitations of current statistical tests in small pre-clinical tumor xenograft studies.
  • To propose a novel statistical method that maintains accurate type-I error rates.
  • To provide practical guidelines for sample size determination in these experiments.

Main Methods:

  • Demonstration of type-I error rate deviations in traditional tests using simulated skewed data.
Keywords:
Log-normal distributionmodified singed log-likelihood ratio testpre-clinicalsample size calculationtumor xenograft experiment

Related Experiment Videos

  • Development and proposal of a modified signed log-likelihood ratio test (MSLRT).
  • Simulation studies to evaluate MSLRT performance across various sample sizes and data distributions.

    • Main Results:

    • Traditional statistical tests show substantial type-I error rate deviations with small, skewed sample sizes.
    • The proposed MSLRT demonstrates consistent and symmetric type-I error rates close to the nominal level.
    • Generated sample size tables tailored for common tumor xenograft experiment scenarios.

    Conclusions:

    • The MSLRT is a robust method for analyzing pre-clinical tumor xenograft data, ensuring reliable type-I error control.
    • The developed sample size tables offer practical guidance for researchers, optimizing mouse usage.
    • Accurate statistical methods are crucial for the validity and efficiency of pre-clinical cancer research.